X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALEMBIC PHARMA Fact Sheet, ALEMBIC PHARMA Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA Fact Sheet   (APLL)

Here is the latest financial fact sheet of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA quarterly results and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

ALEMBIC PHARMA Price History

Price Rs 498.5
Mkt Cap Rs m 93,968
Vol '000 0.1
P/E X 25.7
P/CF X 11.9
EPS (TTM) Rs 19.4
% ch % -0.1
No. of shares m 188.52
% ch week % 0.4
% ch 1-mth % 1.6
% ch 12-mth % -26.0
52 week H/L Rs 709.3/469.8
(As on Oct 23, 2017 09:32:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ALEMBIC PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
ALEMBIC PHARMA EQUITY SHARE DATA
High Rs51113310495792 
Low Rs3448103228443 
Sales per share (Unadj.) Rs77.780.698.8109.1167.0 
Earnings per share (Unadj.) Rs6.98.812.515.038.2 
Diluted earnings per shareRs6.98.812.515.038.2 
Cash flow per share (Unadj.) Rs8.710.614.617.442.0 
Dividends per share (Unadj.) Rs1.402.503.003.504.00 
Adj. dividends per shareRs1.402.503.003.504.00 
Dividend yield (eoy) %3.33.11.51.00.6 
Book value per share (Unadj.) Rs21.026.735.846.984.9 
Adj. book value per shareRs21.026.735.846.984.9 
Shares outstanding (eoy) m188.52188.52188.52188.52188.52 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.51.02.13.33.7 
Avg P/E ratio x6.29.116.524.116.2 
P/CF ratio (eoy) x4.97.614.120.814.7 
Price / Book Value ratio x2.03.05.87.77.3 
Dividend payout %20.328.524.023.310.5 
Avg Mkt Cap Rs m8,01215,11938,93968,122116,383 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,6851,9382,4703,0684,214 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
ALEMBIC PHARMA INCOME DATA
Net Sales Rs m14,65415,20418,63220,56131,487 
Other income Rs m1439322355 
Total revenues Rs m14,66815,24318,66420,58431,542 
Gross profit Rs m2,1942,5203,5774,03010,060 
Depreciation Rs m337350405444722 
Interest Rs m262146981837 
Profit before tax Rs m1,6102,0643,1063,5919,356 
Minority Interest Rs m00000 
Prior Period Items Rs m0002-2 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3094117517642,160 
Profit after tax Rs m1,3011,6532,3552,8297,194 
Gross profit margin %15.016.619.219.631.9 
Effective tax rate %19.219.924.221.323.1 
Net profit margin %8.910.912.613.822.8 
ALEMBIC PHARMA BALANCE SHEET DATA
Current assets Rs m6,8766,3227,0158,90715,066 
Current liabilities Rs m5,3494,4164,4746,8417,674 
Net working cap to sales %10.412.513.610.123.5 
Current ratio x1.31.41.61.32.0 
Inventory Days Days6464616867 
Debtors Days Days5056546441 
Net fixed assets Rs m3,2613,7654,1765,9478,237 
Share capital Rs m377377377377377 
"Free" reserves Rs m3,2034,5826,2358,37415,416 
Net worth Rs m3,9505,0296,7568,84616,005 
Long term debt Rs m9497055221880 
Total assets Rs m10,51910,47812,17316,41224,594 
Interest coverage x7.115.232.7202.7255.2 
Debt to equity ratio x0.20.10.100 
Sales to assets ratio x1.41.51.51.31.3 
Return on assets %14.917.220.217.329.4 
Return on equity %32.932.934.932.044.9 
Return on capital %38.238.544.040.058.7 
Exports to sales %31.930.640.339.355.7 
Imports to sales %12.510.29.510.010.4 
Exports (fob) Rs m4,6804,6507,5028,08517,551 
Imports (cif) Rs m1,8321,5541,7652,0503,283 
Fx inflow Rs m4,7964,8027,7208,28417,811 
Fx outflow Rs m2,2752,1992,6283,1475,318 
Net fx Rs m2,5212,6035,0925,13712,493 
ALEMBIC PHARMA CASH FLOW
From Operations Rs m 1,418 2,648 2,400 1,718 9,304 
From Investments Rs m -564 -670 -811 -2,556 -3,105 
From Financial Activity Rs m -446 -2,288 -1,511 867 -1,959 
Net Cashflow Rs m 408 -310 79 29 4,240 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 74.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 2.9%
FIIs 9.1%
ADR/GDR 0.0%
Free float 13.9%
Shareholders 49,328
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Alembic Road, ,Vadodara,Gujarat - 390 003
E-MAIL apl.investors@alembic.co.in WEB www.alembic-india.com
TELEPHONE (0265) 2282 550 FAX (0265) 2282 506
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, B-102-103, Shangrila Complex, Akota, Vadodara-20
AUDITOR K. S. Aiyar & Co.
CHM: Chirayu R. Amin (MD) COMP SEC: Rajkumar Baheti YEAR OF INC: 2010 BSE CODE: 533573 FV (Rs): 2 DIV YIELD (%): 0.8

More Pharmaceuticals Company Fact Sheets:   ORCHID PHARMA LTD  LUPIN LTD  FDC LTD.  SANOFI INDIA  J.B.CHEMICALS  

Compare ALEMBIC PHARMA With:   ORCHID PHARMA LTD  LUPIN LTD  FDC LTD.  SANOFI INDIA  J.B.CHEMICALS  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Views on news

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Timeless Stocks on the Electric Car Assembly Line(The 5 Minute Wrapup)

Oct 10, 2017

Are they on their way to create Coca Cola-like wealth?

Why Merger of Public Sector Banks Continues to Be a Bad Idea(Vivek Kaul's Diary)

Oct 10, 2017

There is enough research evidence that suggests that most mergers don't work.

Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)

Oct 16, 2017

Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.

Mutual Funds Re-categorised... But What About Stocks?(Daily Profit Hunter)

Oct 11, 2017

The market regulator can solve systemic issues but you must tackle the behavioral biases on your own.

Companies Are Wary of Borrowing(Chart Of The Day)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - ALEMBIC LTD COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS